Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients.

Francesca LigorioLuca ZambelliAchille BottiglieriLorenzo CastagnoliEmma ZattarinRiccardo LobefaroArianna OttiniAndrea VingianiSerenella M PupaGiulia V BianchiGiuseppe CapriGiancarlo PruneriFilippo de Braud

Published in: Therapeutic advances in medical oncology (2021)

High BMI is associated with worse clinical outcomes in early-stage HR-/HER2+ BC patients treated with trastuzumab-containing adjuvant biochemotherapy, while baseline hyperglycemia could be a predictor of worse RFS in HR+/HER2+ BC patients. Prospective studies are needed to investigate if modifying patient BMI/glycemia during treatment can improve clinical outcomes.

Keyphrases

early stage
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
body mass index
positive breast cancer
squamous cell carcinoma
oxidative stress
case report
epidermal growth factor receptor
sentinel lymph node
physical activity
rectal cancer